Collaborative Drug Discovery

Mitarbeit: Murad, Ferid; Herausgegeben von Chaguturu, Rathnam

• Gebundenes Buch

Produktbeschreibung

Can academia save the pharmaceutical industry?

The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement.
Gain global perspectives on the benefits and potential issues surrounding collaborative innovation
Discover how industries can come together to prevent another "Pharma Cliff"
Learn how nonprofits are becoming the driving force behind innovation
Read case studies of specific academia-pharma partnerships for real-life examples of successful collaboration
Explore government initiatives that help foster cooperation between industry and academia

Dr. Chaguturu's thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate.

Produktdetails

• Wiley Series on Technologies for the Pharmaceutical Industry
• Verlag: Wiley & Sons
• 1. Auflage
• Seitenzahl: 752
• Erscheinungstermin: 14. April 2014
• Englisch
• Abmessung: 240mm x 161mm x 45mm
• Gewicht: 1293g
• ISBN-13: 9780470917374
• ISBN-10: 0470917377
• Artikelnr.: 39524797

Autorenporträt

RATHNAM CHAGUTURU, PHD, is the Founder & CEO of iDDPartners, a nonprofit think-tank focused on pharmaceutical innovation. He has more than thirty years of experience in executing new lead discovery projects and forging discovery partnerships. He is the Founding President of the International Chemical Biology Society and Editor-in-Chief of Combinatorial Chemistry and High Throughput Screening. He serves on several other editorial and scientific advisory boards along with NIH Study Sections, is the recipient of several awards, and is a much sought-after speaker at major national and international conferences, passionately advocating the virtues of collaborative partnerships in addressing the pharmaceutical innovation crisis.

Inhaltsangabe

Foreword xv by Ferid Murad Preface xix About the Book xxv About the Editor
xxvii Contributors xxix PART I: PERSPECTIVES ON COLLABORATIVE INNOVATION 1
If I have seen further it is by standing on the shoulders of giants.
--Isaac Newton 1 PRODUCTIVE RELATIONSHIPS IN RESEARCH AND DEVELOPMENT
BETWEEN GOVERNMENT, INDUSTRY, AND UNIVERSITIES 3 Wyatt R. Hume 2 DIVIDED WE
FALL 11 William B. Mattes 3 INNOVATION: OPEN SOURCE AND NONPROFIT MODELS IN
DRUG DISCOVERY 21 James M. Shaeffer and Sarah MacDonald 4 THE CHANGING FACE
OF INNOVATION IN DRUG DISCOVERY 31 Litao Zhang and Carl Decicco 5 CURRENT
TRENDS IN COLLABORATIVE DRUG DISCOVERY AND STRATEGIES TO DE-RISK
PRECOMPETITIVE INITIATIVES 57 Anuradha Roy and Rathnam Chaguturu 6 A
PERSPECTIVE ON THE EVOLUTION OF COLLABORATIVE DRUG DISCOVERY AND FUTURE
CHALLENGES 75 Christopher A. Lipinski PART II: GOVERNMENTAL INITIATIVES
ACCELERATE PRECOMPETITIVE COLLABORATION 85 Governments will always play a
huge part in solving big problems. . . . They also fund basic research,
which is a crucial component of the innovation that improves life for
everyone. --Bill Gates 7 THE VALUE OF UNIVERSITY-INDUSTRY PARTNERSHIPS 87
Anthony M. Boccanfuso 8 TRENDS IN THE PUBLIC SECTOR ADOPTION OF
TRANSLATIONAL RESEARCH APPROACHES 99 Mark A. Scheideler 9 PARTNERSHIPS FOR
DRUG REPOSITIONING: LESSONS FROM THE CTSA PHARMACEUTICAL ASSETS PORTAL 115
Kate Marusina, Dean J. Welsch, Lynn Rose, Doug Brock, Nathan Bahr, Aaron M.
Cohen, Rafael A. Gacel-Sinclair, Pakou Vang, Peter G. Ruminski, Bruce E.
Bloom, Pamela Nagasawa, and Betty P. Guo 10 DEVELOPMENT PROGRAMS AT THE
U.S. NATIONAL CANCER INSTITUTE: USE OF PUBLIC-PRIVATE PARTNERSHIPS AS A
CATALYST TO ADVANCE CANCER THERAPY 135 Jason V. Cristofaro 11 NONINDUSTRIAL
PHARMACEUTICAL RESEARCH IN THE BRIC COUNTRIES: LESSONS FOR DRUG DISCOVERY
PARTNERSHIPS WITH ACADEMIC AND GOVERNMENTAL INSTITUTIONS 159 John Watson 12
DEATH OF DRUGS AND REBIRTH OF HEALTH CARE: INDIAN RESPONSE TO DISCOVERY
IMPASSE 173 Bhushan Patwardhan PART III: A GAME CHANGER FOR AVERTING FUTURE
PHARMA CLIFF 195 Coming together is a beginning, staying together is
progress, and working together is success. --Henry Ford 13 ACCELERATING
INNOVATION IN THE BIOSCIENCE REVOLUTION 197 Bernard H. Munos 14
VALUE-DRIVEN DRUG DEVELOPMENT: UNLOCKING THE VALUE OF YOUR PIPELINE 213
Valentina Sartori, Michael Steinmann, Petra Jantzer, and Matthias Evers 15
UNLOCKING THE MARKET POTENTIAL OF ACADEMIC RESEARCH 221 Assem S. el
Baghdady and Yasser M.S. el Baghdady 16 COLLABORATIVE INNOVATION IN
PHARMACEUTICAL INDUSTRY: APPROACHES AND REQUIREMENTS 255 Monika Lessl and
Khusru Asadullah 17 CLOSE CONTACT: A COLOCATION MODEL FOR
ACADEMIC-INDUSTRIAL PARTNERSHIPS IN DRUG DISCOVERY 267 Peter A. Covitz and
Terrence D. Ruddy 18 SUCCESS FACTORS AND OBSTACLES IN ACADEMIA-INDUSTRY
PARTNERSHIPS: A CASE STUDY OF A GRADUATE PROGRAM WITHIN THE
BAYER-UNIVERSITY OF COLOGNE "PRIVILEGED PARTNERSHIP" 279 Stefan Herzig,
Marion Rozowski, and Ingo Flamme 19 ACADEMIC, COMMERCIAL, AND BIODEFENSE
CASE STUDIES FOR COLLABORATIVE DRUG DISCOVERY: POTENTIAL FOR DISRUPTING
DRUG DISCOVERY 303 Barry A. Bunin and Sean Ekins 20 ACCESS PLATFORM: A
STREAMLINED INTEGRATIVE PARTNERING PROCESS AT SANOFI TO COMMERCIALIZE
UNIVERSITY-BASED INTELLECTUAL PROPERTY 319 Paul R. Eynott and Carole Fages
21 ENTREPRENEURSHIP: DRUG DISCOVERY INNOVATION AT START-UP AND MEDIUM-SIZED
BIOTECHNOLOGY COMPANIES 341 Allen B. Reitz and Kathleen M. Czupich 22
CHEMICAL CONSULTING 355 Lester A. Mitscher PART IV: NONPROFITS DRIVE
BENCH-TO-BEDSIDE INNOVATION 367 Can't afford to innovate? Open up! --Henry
Chesbrough 23 OPEN SOURCE DRUG DISCOVERY FOR NEGLECTED DISEASES 369 Tonny
Johnson and Sanchayita Kar 24 THE MYELIN REPAIR FOUNDATION ACCELERATED
RESEARCH COLLABORATIONTM MODEL: INNOVATIVE DISRUPTION IN BIOMEDICAL
RESEARCH 385 Gali Hagel 25 FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF
CHDI FOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED TO HUNTINGTON'S
DISEASE 411 Allan J. Tobin 26 LESSONS FROM THE PAST AS A MEANS TO THE
FUTURE: INSTITUT PASTEUR AS A MODEL STRATEGY 437 Spencer L. Shorte 27
SEEDING OPEN INNOVATION DRUG DISCOVERY AND TRANSLATIONAL COLLABORATIONS TO
LEVERAGE GOVERNMENT FUNDING: A CASE STUDY OF STRATEGIC PARTNERSHIP BETWEEN
SANFORD-BURNHAM AND MAYO CLINIC 451 Thomas D.Y. Chung, Sundeep Khosla,
Andrew D. Badley, and Michael R. Jackson PART V: ACADEMIC SCREENING CENTERS
COME OF AGE 487 Open access high-throughput drug discovery in the public
domain is a Mount Everest in the making. --Rathnam Chaguturu 28 FINDING THE
MIDDLE GROUND: DRUG DISCOVERY TECHNOLOGY IN THE ERA OF ACADEMIC SCREENING
CENTERS 489 Nathan S. Blow 29 OPEN INNOVATION-BASED DRUG DISCOVERY IN
EUROPE: SOME EXAMPLES OF NATIONAL AND TRANSNATIONAL EUROPEAN INITIATIVES
INTEGRATING CHEMISTRY, BIOLOGY, AND TECHNOLOGY PLATFORMS 499 Philip Gribbon
30 IN SICKNESS AND IN HEALTH: A SHOTGUN MARRIAGE THAT IS FLOURISHING 517
Horst Flotow and Alex Matter 31 A FLEXIBLE MODEL FOR COMPOUND MANAGEMENT
FACILITIES TO STIMULATE COLLABORATIONS IN THE LIFE SCIENCES 533 David Camp
PART VI: INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER 563 Everything that
can be invented has been invented. --Charles Duell 32 SUCCESSFUL TECHNOLOGY
TRANSFER: LESSONS FROM THE TRANSLATIONAL MEDICINE RESEARCH COLLABORATION
565 Assem S. el Baghdady 33 CHALLENGES AND OPPORTUNITIES IN COMMERCIALIZING
ACADEMIC DRUG DISCOVERIES 577 Christopher Paschall 34 THE PIVOTAL ROLE OF
THE ACADEMIC ENTREPRENEUR AND THE ENTREPRENEURIAL UNIVERSITY IN GLOBAL LIFE
SCIENCES 609 Donna Marie De Carolis PART VII: THE FINAL FRONTIER 621 No one
can whistle a symphony; it takes a whole orchestra to play it. --Halford E.
Luccock 35 THE CORE MODEL: DRUG DISCOVERY AND DEVELOPMENT VIA EFFECTIVE
TRANSLATIONAL SCIENCE AND PUBLIC-PRIVATE COLLABORATION 623 Ibis
Sánchez-Serrano 36 USING MARKET-DRIVEN COLLABORATION TO ACCELERATE
INNOVATION IN BIOMEDICINE 653 Elizabeth Iorns 37 THE COST OF TAKING EYES
OFF THE TRUE END USER: FOCUS ON PATIENT NEEDS AND OUTCOMES 663 Deborah E.
Collyar 38 TO LEASH OR UNLEASH THE POWER OF PUBLIC-PRIVATE COLLABORATION:
IN HEALTH AND DISEASE 679 Hakim Djaballah Index 687